Glimepiride
Product Images NDC 21695-993

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Glimepiride (NDC 21695-993). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure.jpg (2001c00c 89ba 4d36 B39b A5374a368427 01)

Chemical structure diagram of the active ingredient, Glimepiride, showing its molecular components and bonds in a two-dimensional format.*

FDA Label Image

Table1.jpg (2001c00c 89ba 4d36 B39b A5374a368427 02)

A data table comparing pharmacokinetic parameters of Glimepiride in volunteers and patients with Type 2 diabetes. It includes Cmax (ng/mL), Tmax (hours), CL/f (mL/min), Vd/f (L), and T1/2 (hours) values for single doses and multiple doses, showing mean and standard deviation values across different dose levels and patient groups.*

FDA Label Image

Table2.jpg (2001c00c 89ba 4d36 B39b A5374a368427 03)

A data table presenting mean baseline HbA1c values and changes from baseline, along with adjusted treatment differences and 95% confidence intervals, for naïve and previously treated patients using Metformin or Glimepiride. The table includes patient counts and comparative statistics for both medications in each patient group.*

FDA Label Image

Table3.jpg (2001c00c 89ba 4d36 B39b A5374a368427 04)

A data table comparing weight changes (in kilograms) between Metformin and Glimepiride groups. It lists baseline mean weights, mean change from baseline, and adjusted treatment difference with confidence intervals for both treatments.*

FDA Label Image

Table4.jpg (2001c00c 89ba 4d36 B39b A5374a368427 05)

A data table presenting adverse events occurring in more than 1% of Glimepiride patients compared to placebo. It lists the number and percentage of patients reporting dizziness, asthenia, headache, and nausea among those treated with Glimepiride and placebo.*

FDA Label Image

Glimepiride 4mg (2001c00c 89ba 4d36 B39b A5374a368427 06)

Label for Glimepiride 4 mg tablets, bottle of 90 tablets, labeled with NDC 21695-747-90. The label notes each tablet contains 4 mg of Glimepiride. The manufacturer is Dr. Reddy's Laboratories Limited, India, and the product is packaged by Physician Partner in Thousand Oaks, CA. Storage instructions specify keeping tablets at 15-30°C and out of children's reach.*

FDA Label Image

Glimepiride 2mg (2001c00c 89ba 4d36 B39b A5374a368427 07)

Glimepiride 2mg tablet bottle label by Physician Partner, a division of Rebel Distributors Corp. The label states prescription use only, contains 30 tablets, with directions indicating once-a-day dosing. Tablets contain Glimepiride USP 2mg each. Storage instructions require controlled room temperature 15°-30°C (59°-86°F). Manufacturer listed as Dr. Reddy's Laboratories Limited, India.*

FDA Label Image

Glimepiride 1mg (2001c00c 89ba 4d36 B39b A5374a368427 08)

Label for Glimepiride 1 mg tablets, once-a-day dosage, with a quantity of 120 tablets. The label indicates the product is prescription-only and identifies the manufacturer as Dr. Reddy's Laboratories Limited, India. The packager is Physician Partner, Thousand Oaks, CA, with storage instructions at controlled room temperature.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.